KR20230110793A9 - 플루마제닐 및 날트렉손을 포함하는 조성물 및 이의 사용 방법 - Google Patents

플루마제닐 및 날트렉손을 포함하는 조성물 및 이의 사용 방법

Info

Publication number
KR20230110793A9
KR20230110793A9 KR1020237021602A KR20237021602A KR20230110793A9 KR 20230110793 A9 KR20230110793 A9 KR 20230110793A9 KR 1020237021602 A KR1020237021602 A KR 1020237021602A KR 20237021602 A KR20237021602 A KR 20237021602A KR 20230110793 A9 KR20230110793 A9 KR 20230110793A9
Authority
KR
South Korea
Prior art keywords
flumazenil
naltrexone
compositions
methods
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237021602A
Other languages
English (en)
Korean (ko)
Other versions
KR20230110793A (ko
Inventor
리 에릭 로드니
다니엘 존 자나르도
줄리안 칙
Original Assignee
트렉사팜 피티와이 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020904390A external-priority patent/AU2020904390A0/en
Application filed by 트렉사팜 피티와이 엘티디 filed Critical 트렉사팜 피티와이 엘티디
Publication of KR20230110793A publication Critical patent/KR20230110793A/ko
Publication of KR20230110793A9 publication Critical patent/KR20230110793A9/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237021602A 2020-11-27 2021-11-26 플루마제닐 및 날트렉손을 포함하는 조성물 및 이의 사용 방법 Pending KR20230110793A9 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020904390 2020-11-27
AU2020904390A AU2020904390A0 (en) 2020-11-27 Compositions and methods
PCT/AU2021/051413 WO2022109677A1 (en) 2020-11-27 2021-11-26 Compositions comprising flumazenil and naltrexone and methods for use thereof

Publications (2)

Publication Number Publication Date
KR20230110793A KR20230110793A (ko) 2023-07-25
KR20230110793A9 true KR20230110793A9 (ko) 2024-11-13

Family

ID=81753640

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237021602A Pending KR20230110793A9 (ko) 2020-11-27 2021-11-26 플루마제닐 및 날트렉손을 포함하는 조성물 및 이의 사용 방법

Country Status (9)

Country Link
US (2) US12521401B2 (https=)
EP (1) EP4251168A4 (https=)
JP (1) JP2024501919A (https=)
KR (1) KR20230110793A9 (https=)
CN (2) CN116648246A (https=)
AU (2) AU2021388076B2 (https=)
CA (1) CA3201498A1 (https=)
IL (1) IL303117A (https=)
WO (1) WO2022109677A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025106574A1 (en) * 2023-11-14 2025-05-22 Aardwolf Therapeutics, Inc. Flumazenil for treating post-traumatic stress disorder and anxiety

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008538748A (ja) 2005-04-07 2008-11-06 ハイシアム， インコーポレイテッド 不安、物質乱用及び依存の予防のための改良型方法及び組成物
JP2009517393A (ja) * 2005-11-28 2009-04-30 オレキシジェン・セラピューティクス・インコーポレーテッド 不安症の治療方法
ES2289935B1 (es) 2006-07-14 2008-12-16 Juan Jose Legarda Ibañez Empleo de flumazenilo en la elaboracion de un medicamento para el tratamiento de la patologia depresiva.
US9283212B2 (en) * 2009-02-20 2016-03-15 Palmaya Pty Ltd Pharmaceutical preparation and delivery system
US20150111916A9 (en) * 2010-04-29 2015-04-23 Annette Channa Toledano Treatment of pain using a composition of opioid/Toll-like receptor 4 antagonists and dextro enantiomers thereof
WO2014120936A2 (en) * 2013-01-30 2014-08-07 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
WO2014186824A1 (en) * 2013-05-20 2014-11-27 Palmaya Pty Ltd Treatment of neurological and other disorders
WO2015054730A1 (en) * 2013-10-14 2015-04-23 Palmaya Pty Ltd Compositions and methods of administering same
WO2020181340A1 (en) * 2019-03-14 2020-09-17 Palmaya Pty Ltd Treatment of inflammatory diseases of the central nervous system

Also Published As

Publication number Publication date
AU2021388076A9 (en) 2024-08-08
CN121695144A (zh) 2026-03-20
AU2021388076B2 (en) 2025-08-14
US20240000796A1 (en) 2024-01-04
WO2022109677A1 (en) 2022-06-02
EP4251168A1 (en) 2023-10-04
CN116648246A (zh) 2023-08-25
CA3201498A1 (en) 2022-06-02
JP2024501919A (ja) 2024-01-17
IL303117A (en) 2023-07-01
EP4251168A4 (en) 2024-11-06
AU2025267401A1 (en) 2025-12-04
KR20230110793A (ko) 2023-07-25
US20260102405A1 (en) 2026-04-16
US12521401B2 (en) 2026-01-13
AU2021388076A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
IL291933A (en) Oligonucleotide compositions and methods of use thereof
IL284050A (en) Substituted pyrazolopyrimes and substituted purines and their use as ubiquitin specific-processing protease 1 (usp1) inhibitors
JP2018172409A5 (ja) １５−ｈｅｐｅを含む組成物および同組成物を使用する方法
IL287768A (en) Kcnt1 inhibitors and methods of use
IL287751A (en) Kcnt1 inhibitors and methods of use
EP3452597A4 (en) METHODS AND COMPOSITIONS FROM BIOLOGICALLY ACTIVE SUBSTANCES
SI3555070T1 (sl) Amino-substituirane heterociklične spojine kot inhibitorji ehmt2 in načini njihove uporabe
EP3407976A4 (en) COMPOSITIONS AND USES OF ALPHA ADRENERGEN AGENTS
IL281938A (en) Stable semaglutide compositions and uses thereof
EP3856742C0 (en) TRICYCLIC JANUS KINASE 1 INHIBITORS, AND RELATED COMPOSITIONS AND METHODS
EP3743525A4 (en) PROXIMITY DETECTION METHODS AND COMPOSITIONS
EP4399306A4 (en) PAH COMPOSITIONS AND MODULATION METHODS
IL276135A (en) Preparations and methods of use
PL4208046T3 (pl) Kompozycje i sposoby
DK3710036T3 (da) Stable ascorbic acid compositions and methods of using the same
IL271464A (en) Nk-1 antagonist compositions and methods for use in treating depression
IL283787A (en) Herboxidiene antibody-drug conjugates and methods of use
ZA202100780B (en) Bismuth-thiol compositions and methods of use
IL309079A (en) Methods and compositions
EP3630772A4 (en) METHOD OF MANUFACTURING AND USING PDE9 INHIBITORS
EP3844500A4 (en) RP182 COMPOSITIONS AND METHODS
PL4090332T3 (pl) Kompozycje podstawionych pirazolopirymidyn i ich zastosowania
EP4146151A4 (en) FURANIC SURFACTANT COMPOSITIONS AND METHODS
IL311867A (en) Trem compositions and methods of use
GB2622995B (en) CAS13-based compositions and methods of use thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230626

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PG1701 Publication of correction
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241106

Comment text: Request for Examination of Application